Back

De-escalation vs. early cessation of DAPT for patients at high bleeding risk

1 September 2024 (12:30 - 12:45)
Organised by: Logo
Congress Presentation Part of: Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions Antiplatelet Agents ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Pratap Chandra Rath

Apollo hospitals, Hyderabad (India)

3 More presentations in this session

Presentation thumbnail
When should we prolong DAPT beyond 12 months?
Doctor M. Das (Kolkata, IN)
Slides Video
Presentation thumbnail
Is aspirin the preferred monotherapy after DAPT?
Professor B. Rocca (Casamassima, IT)
Slides Video
Presentation thumbnail
Machine learning to determine the optimal mode and duration of DAPT
Doctor B. Vogel (San Diego, US)
Slides Video

Access the full session

Session thumbnail
Personalised dual antiplatelet therapy (DAPT) after acute coronary syndromes: difficult decisions
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Antiplatelet therapy in patients with coronary artery disease: striking the right balance
thumbnail
Congress Presentation
Dual antiplatelet therapy de-escalation or abbreviation: if I had to choose one of them
thumbnail
Congress Presentation
De-escalating dual antiplatelet therapy after acute coronary syndrome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources